theseus pharmaceuticals is passionately committed to outsmarting cancer resistance. cancer is constantly mutating, allowing it to evade initially effective oncology treatments. theseus believes we can predict how cancer will change, enabling new therapies to stay ahead of future mutations and overcome the demonstrated burden of treatment resistance. led by a team of pioneers in the discovery and development of tyrosine kinase inhibitors (tkis), we are developing best-in-class, pan-variant kinase inhibitors, to shape the future of targeted oncology.
Company profile
Ticker
THRX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Theseus Securities Corporation ...
IRS number
830712806
THRX stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
26 Feb 24
EFFECT
Notice of effectiveness
16 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Feb 24
POS AM
Prospectus update (post-effective amendment)
14 Feb 24
8-K
Completion of Acquisition or Disposition of Assets
14 Feb 24
SC TO-T/A
Third party tender offer statement (amended)
14 Feb 24
SC 14D9/A
Tender offer solicitation (amended)
14 Feb 24
25-NSE
Exchange delisting
14 Feb 24
SC 14D9/A
Tender offer solicitation (amended)
7 Feb 24
Latest ownership filings
SC 13D/A
TANG CAPITAL PARTNERS LP
16 Feb 24
4
Kathy Yi
14 Feb 24
4
Steven H Stein
14 Feb 24
4
Change in insider ownership
14 Feb 24
4
DONALD J HAYDEN JR
14 Feb 24
4
CARL L GORDON
14 Feb 24
4
Iain D. Dukes
14 Feb 24
4
Bradford D. Dahms
14 Feb 24
SC 13G/A
Frazier Life Sciences Public Fund, L.P.
13 Feb 24
SC 13D/A
TANG CAPITAL PARTNERS LP
12 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 47.29 mm | 47.29 mm | 47.29 mm | 47.29 mm | 47.29 mm | 47.29 mm |
Cash burn (monthly) | 316.33 k | 5.72 mm | 5.47 mm | 5.54 mm | 3.68 mm | 4.14 mm |
Cash used (since last report) | 2.11 mm | 38.12 mm | 36.43 mm | 36.94 mm | 24.49 mm | 27.56 mm |
Cash remaining | 45.18 mm | 9.18 mm | 10.86 mm | 10.36 mm | 22.80 mm | 19.74 mm |
Runway (months of cash) | 142.8 | 1.6 | 2.0 | 1.9 | 6.2 | 4.8 |
Institutional ownership, Q3 2023
91.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 65 |
Opened positions | 10 |
Closed positions | 16 |
Increased positions | 19 |
Reduced positions | 21 |
13F shares | Current |
---|---|
Total value | 94.74 bn |
Total shares | 40.29 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Orbimed Advisors | 17.71 mm | $47.65 bn |
Foresite Capital Fund V | 4.11 mm | $35.09 mm |
Foresite Capital Management V | 4.11 mm | $11.05 bn |
Frazier Life Sciences Management | 2.25 mm | $6.05 bn |
Millennium Management | 1.72 mm | $4.62 bn |
BLK Blackrock | 1.34 mm | $3.61 bn |
T. Rowe Price | 1.22 mm | $3.27 bn |
Frazier Life Sciences Public Fund | 908.27 k | $8.72 mm |
Vanguard | 789.12 k | $2.12 bn |
Omega Fund Management | 711.48 k | $1.91 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Nov 23 | William Shakespeare | Common Stock | Option exercise | Acquire M | No | No | 0.32 | 251,084 | 80.35 k | 639,408 |
6 Nov 23 | William Shakespeare | Stock Option Common Stock | Option exercise | Dispose M | No | No | 0.32 | 251,084 | 80.35 k | 93,260 |
17 Jul 23 | Foresite Capital Management V | Common Stock | Buy | Acquire P | Yes | No | 2.97 | 176,550 | 524.35 k | 1,385,825 |
17 Jul 23 | Foresite Capital Management V | Common Stock | Buy | Acquire P | Yes | No | 2.97 | 523,450 | 1.55 mm | 4,108,796 |
17 Jul 23 | Orbimed Advisors | Common Stock | Buy | Acquire P | Yes | No | 3.05 | 151,450 | 461.92 k | 650,600 |
17 Jul 23 | Orbimed Advisors | Common Stock | Buy | Acquire P | Yes | No | 3.05 | 328,482 | 1.00 mm | 17,063,000 |
17 Jul 23 | Gordon Carl L | Common Stock | Buy | Acquire P | Yes | No | 3.05 | 151,450 | 461.92 k | 650,600 |
17 Jul 23 | Gordon Carl L | Common Stock | Buy | Acquire P | Yes | No | 3.05 | 328,482 | 1.00 mm | 17,063,000 |
13 Jun 23 | Dukes Iain D. | RSU Common Stock | Grant | Acquire A | No | No | 0 | 3,250 | 0.00 | 3,250 |
13 Jun 23 | Dukes Iain D. | Stock Option Common Stock | Grant | Acquire A | No | No | 9.61 | 19,500 | 187.40 k | 19,500 |
Press releases
Theseus Pharmaceuticals Announces Closing of Tender Offer
14 Feb 24
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - AMAM, TGAN, CSTR, THRX
5 Feb 24
Concentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus Pharmaceuticals
30 Jan 24
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates CSTR, PGTI, THRX
25 Jan 24
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates PGTI, X, THRX, AYX
23 Jan 24